This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Akebia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $1.038. Akebia Therapeutics's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.
As of today (2024-04-25), Akebia Therapeutics's share price is $1.37. Akebia Therapeutics's Median PS Value is $0.00. Therefore, Akebia Therapeutics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Akebia Therapeutics's Median PS Value or its related term are showing as below:
AKBA's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.66 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
Akebia Therapeutics Median PS Value Historical Data
The historical data trend for Akebia Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Akebia Therapeutics's Median PS Value
For the Biotechnology subindustry, Akebia Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akebia Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Akebia Therapeutics's Price-to-Median-PS-Value falls into.
Akebia Therapeutics Median PS Value Calculation
Akebia Therapeutics's Median PS Value for today is calculated as
10-Year Median PS Ratio is 0.
Akebia Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.038.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics (NAS:AKBA) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Akebia Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
1.37
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akebia Therapeutics Median PS Value Related Terms
Thank you for viewing the detailed overview of Akebia Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Akebia Therapeutics (Akebia Therapeutics) Business Description
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKBA has been successfully added to your 